載入...
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
BACKGROUND: This study forms part of the first complete characterization of the dose–response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower GP MDI dose range to determine an optimal dose for patients with mode...
Na minha lista:
| 發表在: | Respir Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5009486/ https://ncbi.nlm.nih.gov/pubmed/27586537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-016-0426-4 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|